Welcome to our dedicated page for Coeptis Therapeutics news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics stock.
News and press releases about Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) highlight its evolution as a biopharmaceutical and technology company, its cell therapy platforms, and its corporate transactions. Company announcements describe Coeptis as operating biopharmaceutical divisions focused on cell therapy platforms for cancer, autoimmune, and infectious diseases, alongside a Technology Division built around AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group.
Recent news has emphasized developments in Coeptis’ pipeline and partnerships. The company has reported securing exclusive worldwide development and commercialization rights to the GEAR Cell Therapy Platform and forming GEAR Therapeutics, Inc. to advance GEAR-modified NK cells for a broad range of cancers. SNAP Biosciences, a majority-owned subsidiary, has announced a licensing agreement with Monarch Therapeutics to enhance the SNAP-CAR NK cell therapy platform using small-molecule adaptor technology.
Coverage also includes updates on Coeptis’ hybrid business model and technology initiatives. Articles describe how the NexGenAI platform contributes revenue while the company advances its cell therapy research, and how a co-working technology hub in India supports AI, blockchain, and digital transformation projects for the NexGenAI Affiliates Group.
Another key theme in recent news is corporate strategy and capital structure. Coeptis has announced the extinguishment of a convertible note with YA II PN, Ltd, and multiple releases detail a proposed merger with Z Squared Inc., a Dogecoin-focused digital asset mining company. These items cover the filing and effectiveness of a Form S-4 registration statement, the planned spin-out of biopharmaceutical operations, and the intention for the combined company to focus on digital asset mining. Investors and observers can use this news stream to follow Coeptis’ biopharmaceutical progress, technology partnerships, financing actions, and the status of its planned merger with Z Squared.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Coeptis Therapeutics (NASDAQ: COEP) announced a proposed transaction to acquire assets from Deverra Therapeutics, focusing on NK cell therapies for relapsed/refractory acute myeloid leukemia (AML) and respiratory infections. The agreement grants Coeptis exclusive negotiation rights until August 31, 2023, for two IND applications and Phase 1 trials involving NK cell therapy. This acquisition aims to enhance Coeptis' R&D capabilities and diversify its portfolio by integrating a proven allogeneic platform that requires no HLA matching. With anticipated Phase 1 AML trial data expected in 2H 2023, the deal could significantly expand Coeptis' technological footprint. If completed, Deverra's CSO, Dr. Colleen Delaney, is expected to join Coeptis as Chief Scientific and Medical Officer.
Coeptis Therapeutics Holdings (NASDAQ: COEP) has acquired exclusive rights to negotiate for the acquisition of VyGen-Bio, enhancing its oncology pipeline. The GEAR™ Platform and companion diagnostic technologies from VyGen-Bio will support the development of advanced cell therapies targeting CD38+ cancers, including multiple myeloma. Coeptis will initiate due diligence on VyGen-Bio’s assets, focusing on GEAR-NK cell therapy. The companies aim to leverage their collaboration to improve patient outcomes and expand treatment options in immuno-oncology. Successful completion of this transaction could mark a significant growth milestone for Coeptis.
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that its SNAP-CAR technology was featured in a peer-reviewed article in the Journal of Translational Medicine on March 21, 2023. The SNAP-CAR platform, designed for multi-antigen targeting, aims to enhance the efficacy and safety of CAR T therapies for various cancers. The article highlights its potential to overcome limitations of current CAR T technologies by linking antibodies to universal CAR receptors. Coeptis plans to target HER2-expressing ovarian cancer as part of its first-in-human clinical development program, with the technology licensed from the University of Pittsburgh.